Gina T. Nguyen

Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

N. Krogan, K. Shokat, K. Obernier, 2021, bioRxiv.

Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.

Robert Kiss, Michael Rubin, I. V. Aksenova, 2015, Journal of medicinal chemistry.